
AstraZeneca will invest $50 billion (€42.8 bn) in the US by 2030 in a move to expand its R&D and manufacturing there, the firm announced on Monday.
This comes as the pharmaceutical giant aims to reach the target of $80 billion (€68.5 bn) in revenue by 2030, with 50% of it hoped to come from the US.